ATAI Life Sciences N.V. financial data

Symbol
ATAI on Nasdaq
Industry
Pharmaceutical Preparations
Location
Wallstrasse 16, Berlin, Germany
State of incorporation
Netherlands
Fiscal year end
December 31
Former names
ATAI Life Sciences B.V. (to 6/21/2021)
Latest financial report
10-Q - Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.05 K % -23.2%
Debt-to-equity 18.3 % +29.5%
Return On Equity -14.2 % +73.2%
Return On Assets -12 % +74.2%
Operating Margin -42 K % +21.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 166 M shares +0.01%
Common Stock, Shares, Outstanding 166 M shares +0.16%
Entity Public Float 203 M USD -50.5%
Common Stock, Value, Issued 18.6 M USD +0.16%
Weighted Average Number of Shares Outstanding, Basic 159 M shares +1.99%
Weighted Average Number of Shares Outstanding, Diluted 159 M shares +1.99%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 277 K USD +2.59%
General and Administrative Expense 62.2 M USD -6.29%
Operating Income (Loss) -116 M USD +19.5%
Nonoperating Income (Expense) 84.5 M USD +938%
Income Tax Expense (Benefit) 847 K USD -86.7%
Net Income (Loss) Attributable to Parent -33.8 M USD +77.3%
Earnings Per Share, Basic -0.21 USD/shares +77.9%
Earnings Per Share, Diluted -0.21 USD/shares +77.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 18.9 M USD -89.9%
Other Assets, Current 1.28 M USD -35.4%
Assets, Current 118 M USD -56.1%
Other Long-term Investments 32.8 M USD +461%
Property, Plant and Equipment, Net 920 K USD -17.4%
Operating Lease, Right-of-Use Asset 1.12 M USD -25.1%
Other Assets, Noncurrent 2.57 M USD -19.1%
Assets 269 M USD -4.13%
Accounts Payable, Current 3.84 M USD -21.8%
Accrued Liabilities, Current 10.9 M USD -20.9%
Liabilities, Current 15 M USD -24.8%
Operating Lease, Liability, Noncurrent 907 K USD -23.5%
Other Liabilities, Noncurrent 8.28 M USD +194%
Liabilities 45.9 M USD +14.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -18.9 M USD +9.12%
Retained Earnings (Accumulated Deficit) -578 M USD -6.22%
Stockholders' Equity Attributable to Parent 223 M USD -6.03%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 223 M USD -7.22%
Liabilities and Equity 269 M USD -4.13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.6 M USD -6.93%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 11.5 M USD -28.4%
Common Stock, Shares Authorized 750 M shares 0%
Common Stock, Shares, Issued 166 M shares +0.16%
Common Stock, Par or Stated Value Per Share 0.11 USD/shares -8.33%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.2 M USD -136%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 33.9 M USD -81.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 629 K USD +39.2%
Deferred Tax Assets, Valuation Allowance 90 M USD -5.97%
Deferred Tax Assets, Gross 121 M USD +19.5%
Operating Lease, Liability 1.15 M USD -23.4%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -31.9 M USD +79.6%
Operating Lease, Liability, Current 244 K USD -23%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Unrecognized Tax Benefits 369 K USD
Additional Paid in Capital 801 M USD +2.25%
Depreciation, Depletion and Amortization 83 K USD +27.7%
Deferred Tax Assets, Net of Valuation Allowance 30.8 M USD +473%
Interest Expense 2.72 M USD +76.1%